Answers are grounded in this paper and cite their sources.
Preclinical and phase 1 trials demonstrate potent antiviral activity and safe oral exposure of PF-07321332 in healthy humans, indicating strong clinical potential against COVID-19.
The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part of the healthcare response to countering the ongoing threat presented by COVID-19. Here, we report the discovery and characterization of PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. PF-07321332 has demonstrated oral activity in a mouse-adapted SARS-CoV-2 model and has achieved oral plasma concentrations exceeding the in vitro antiviral cell potency in a phase 1 clinical trial in healthy human participants.
No takes yet. Share an insight, caveat, or question.
Owen et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: